C‐peptide in the natural history of type 1 diabetes
- 6 March 2009
- journal article
- review article
- Published by Wiley in Diabetes/Metabolism Research and Reviews
- Vol. 25 (4), 325-328
- https://doi.org/10.1002/dmrr.943
Abstract
Type 1 diabetes is diagnosed when the patient's endogenous insulin secretion decreases to a level which results in hyperglycemia. After diagnosis, insulin secretion continues to decline. As a reference for clinical trials trying to preserve endogenous beta-cell function in patients with recently diagnosed type 1 diabetes, in this short review I attempt to summarize the natural history of endogenous beta-cell function after the diagnosis of type 1 diabetes.Keywords
This publication has 31 references indexed in Scilit:
- Glucose and C-Peptide Changes in the Perionset Period of Type 1 Diabetes in the Diabetes Prevention Trial–Type 1Diabetes Care, 2008
- Too Much Glucagon, Too Little InsulinDiabetes Care, 2008
- The PTPN22 1858T Gene Variant in Type 1 Diabetes Is Associated With Reduced Residual β-Cell Function and Worse Metabolic ControlDiabetes Care, 2008
- Association of IL-1ra and Adiponectin With C-Peptide and Remission in Patients With Type 1 DiabetesDiabetes, 2008
- Patterns of Metabolic Progression to Type 1 Diabetes in the Diabetes Prevention Trial–Type 1Diabetes Care, 2006
- Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotypeDiabetes/Metabolism Research and Reviews, 2005
- Temporary Preservation of β-Cell Function by Diazoxide Treatment in Childhood Type 1 DiabetesDiabetes Care, 2004
- Prognostic Factors for the Course of Cell Function in Autoimmune DiabetesJournal of Clinical Endocrinology & Metabolism, 2000
- Beneficial effects of C‐peptide on incipient nephropathy and neuropathy in patients with Type 1 diabetes mellitusDiabetic Medicine, 2000
- A Randomized Trial of Intensive Insulin Therapy in Newly Diagnosed Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1989